immunity News and Research

RSS

What do we know about the SARS-CoV-2 vaccines so far?

A new study surveys what we know so far about SARS-CoV-2 vaccine candidates from advanced clinical trials.

27 Jan 2021

SARS-CoV-2 spike may impair antigen presentation by CD8 T cells

A new study published on the bioRxiv preprint server aims to identify specific viral epitopes on the spike protein from various regions of the spike protein and the T cell responses they evoke.

27 Jan 2021

Pain-free microneedle patch can capture biomarkers from interstitial fluid

Blood draws are no fun. They hurt. Veins can burst, or even roll - like they're trying to avoid the needle too, Oftentimes, doctors use blood samples to check for biomarkers of disease: antibodies that signal a viral or bacterial infection, such as SARS-CoV-2, the virus responsible for COVID-19, or cytokines indicative of inflammation seen in conditions such as rheumatoid arthritis and sepsis.

26 Jan 2021

Antibodies and inflammatory markers may help identify COVID-19 cases and predict severity

A new preprint appearing on the medRxiv server describes the changes that occur in numerous antibodies and inflammatory molecules with age and at varying stages, or severity, of the infection and resulting illness. The results may help to predict the risk in individual cases.

26 Jan 2021

Moderna vaccine fully neutralizes new SARS-CoV-2 variants, study shows

Researchers in the United States have conducted a study showing that Moderna’s mRNA-1273 vaccine neutralizes all circulating variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tested to date.

26 Jan 2021

Microglial cells contribute to the negative mood experienced during neurological diseases

Special immune cells found in the brain, microglia, play a key role in the processes that make you feel uneasy and depressed in correlation with inflammation.

26 Jan 2021

Accelerating vaccine rollout may provide greatest reduction in COVID-19 mortality

A thought-provoking preprint research paper posted to the medRxiv server suggests that among several factors that could potentially contribute to the design of an optimal vaccine strategy aimed at the most significant possible reduction in COVID-19 mortality, timing is likely to be the most important factor.

26 Jan 2021

Recombinant SARS-CoV-2 protein vaccine less immunogenic but more antigenic than expected

Now, a new preprint research paper posted to the medRxiv server presents preliminary results of a stabilized SARS-CoV-2 pre-fusion spike protein vaccine expressed in a baculovirus system (CoV2 preS dTM), with two different adjuvant formulations.

26 Jan 2021

Probiotics as adjuvant therapy for COVID-19 patients

In a recent review published in the Journal of Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Luigi Santacroce and Francesco Inchingolo et al. address the many factors such as dysbiosis (imbalance in the microbiota) that could influence the SARS-CoV-2 infection course.

25 Jan 2021

Herd immunity to SARS-CoV-2 may not be achievable with current vaccines

A recent preprint research paper posted on the medRxiv server asks the question: “Is “herd immunity” to COVID-19 a realistic outcome of any immunization program with the two main vaccines currently licensed in the UK?”

25 Jan 2021

Missing surface protein allows small cell lung cancer cells to hide from immune defenses

Small cell lung cancer (SCLC) cells are missing a surface protein that triggers an immune response, allowing them to hide from one of the body's key cancer defenses, a new study led by UT Southwestern researchers suggests.

25 Jan 2021

Combining anti-tumor antibodies with standard-of-care improves therapeutic outcomes in cancer

The cover for issue 2 of Oncotarget features Figure 4, "Combination therapy TA99/ICB reduced the lung tumor burden in the B16 model of metastases," published in "Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma" by Pérez-Lorenzo, et al. which reported that here, the authors showed that removing immune suppression and enhancing stimulatory signals increased the anti-tumor activity of unmodified TA99 antibodies with a significant reduction of growth of solid tumors and lung metastases in mouse models of melanoma.

25 Jan 2021

Novel neutralizing antibodies targeting SARS-CoV-2 N-terminal domain discovered

A new study by US-based researchers shows the presence of protective antibodies that target the N-terminal domain (NTD) of the spike instead of the spike receptor-binding domain (RBD).

22 Jan 2021

Accurate quantitative COVID-19 antibody test kit by EKF

EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals.

From EKF Diagnostics 22 Jan 2021

People with severe COVID-19 cases may have more protective "memory" T cells

A big question on people's minds these days: how long does immunity to SARS-CoV-2 last following infection?

22 Jan 2021

Trial results support efficacy of incentivizing vaccine adherence

As the United States struggles to control record-breaking increases in COVID-19 infections and hospitalizations, the roll-out of two approved vaccines offers tremendous hope for saving lives and curbing the pandemic.

22 Jan 2021

Prioritizing older adults for COVID-19 vaccination will save more lives

Vaccinating older adults for COVID-19 first will save substantially more U.S. lives than prioritizing other age groups, and the slower the vaccine rollout and more widespread the virus, the more critical it is to bring them to the front of the line.

21 Jan 2021

New model shows key role of innate immunity in controlling COVID-19 viral load

Since SARS-CoV-2 was identified in December 2019, researchers have worked feverishly to study the novel coronavirus. Although much knowledge has been gained, scientists still have a lot to learn about how SARS-CoV-2 interacts with the human body, and how the immune system fights it.

21 Jan 2021

SARS-CoV-2 suppresses host innate immunity

SARS-CoV-2, the virus that causes COVID-19, blocks the processes of innate immune activation that normally direct the production and/or signaling of type I interferon (IFN-I) by the infected cell and tissues.

21 Jan 2021